Thiard News@F4F

@newsen.bsky.social

5 months ago

Oncolytics Biotech® Reveals Promising Anal Cancer Treatment Results, Potential for Accelerated Approval Oncolytics Biotech® Inc. reports groundbreaking results in anal cancer treatment with pelareorep and atezolizumab, achieving a 30% response rate.

Oncolytics Biotech® Reveals Promising Anal Cancer Treatment Results, Potential for Accelerated Approval #USA #San_Diego #Oncolytics_Biotech #pelareorep #Atezolizumab

Thiard News@F4F

@newsen.bsky.social

5 months ago

Oncolytics Biotech Inc. Proposes to Relocate Incorporation to Nevada, Aiming for Greater Efficiency Oncolytics Biotech Inc. is planning to move its jurisdiction of incorporation from Canada to Nevada to optimize operations and enhance shareholder value.

Oncolytics Biotech Inc. Proposes to Relocate Incorporation to Nevada, Aiming for Greater Efficiency #USA #San_Diego #Oncolytics_Biotech #pelareorep #SEC_Filing

Thiard News@F4F

@newsen.bsky.social

6 months ago

Oncolytics Biotech's Promising Update on Pancreatic Cancer Study Design Oncolytics Biotech provides a significant update on its pancreatic cancer study, showcasing a robust trial design focused on patient survival metrics with pelareorep's potential.

Oncolytics Biotech's Promising Update on Pancreatic Cancer Study Design #United_States #San_Diego #pancreatic_cancer #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

6 months ago

Oncolytics Biotech's Progress on the GOBLET Study and Expansion in the U.S. Market Oncolytics Biotech updates on the GOBLET clinical trial, key findings, and U.S. expansion plans, highlighting promising results in gastrointestinal cancer treatment.

Oncolytics Biotech's Progress on the GOBLET Study and Expansion in the U.S. Market #USA #San_Diego #Oncolytics_Biotech #pelareorep #GOBLET_Study

Thiard News@F4F

@newsen.bsky.social

6 months ago

Oncolytics Biotech® Unveils Promising Clinical Results for Pelareorep in Metastatic Colorectal Cancer Treatment Strategy Oncolytics Biotech® has revealed significant findings about pelareorep's effectiveness in combating metastatic colorectal cancer, advancing its regulatory strategy.

Oncolytics Biotech® Unveils Promising Clinical Results for Pelareorep in Metastatic Colorectal Cancer Treatment Strategy #United_States #San_Diego #Oncolytics_Biotech #pelareorep #Metastatic_Colorectal_Cancer

Thiard News@F4F

@newsen.bsky.social

7 months ago

Oncolytics Biotech Shares Positive Safety Data for Pelareorep in Gastrointestinal Cancers Oncolytics Biotech Inc. has announced updated clinical safety data for pelareorep, showing favorable results across various gastrointestinal tumors and treatments.

Oncolytics Biotech Shares Positive Safety Data for Pelareorep in Gastrointestinal Cancers #USA #San_Diego #Cancer_Treatment #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

7 months ago

Oncolytics Biotech® Provides Shareholder Voting Outcomes from Recent Annual Meeting Oncolytics Biotech® has recently announced the outcomes of its Annual General Meeting, revealing the election results and share representation.

Oncolytics Biotech® Provides Shareholder Voting Outcomes from Recent Annual Meeting #United_States #San_Diego #Oncolytics_Biotech #pelareorep #Annual_General_Meeting

Thiard News@F4F

@newsen.bsky.social

7 months ago

Oncolytics Biotech® to Voluntarily Delist from the Toronto Stock Exchange, Focusing on Nasdaq Oncolytics Biotech® Inc. announces its voluntary delisting from the TSX, prioritizing its Nasdaq listing amid strategic shifts to enhance shareholder value.

Oncolytics Biotech® to Voluntarily Delist from the Toronto Stock Exchange, Focusing on Nasdaq #NASDAQ #San_Diego #Canada #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

7 months ago

Oncolytics Biotech's Financial Progress and Future Plans for Pelareorep Oncolytics Biotech recently announced its second-quarter financial results and plans for the immunotherapy Pelareorep, focusing on pancreatic cancer treatment.

Oncolytics Biotech's Financial Progress and Future Plans for Pelareorep #San_Diego #Canada #pancreatic_cancer #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

7 months ago

Oncolytics Biotech® Prepares for 2025 Annual General Meeting and Financial Update Oncolytics Biotech® Inc. announces its 2025 Annual General Meeting and the upcoming second quarter financial results. Important updates are expected.

Oncolytics Biotech® Prepares for 2025 Annual General Meeting and Financial Update #United_States #San_Diego #Immunotherapy #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

8 months ago

Oncolytics Biotech® Pursues FDA Study Approval for Pancreatic Cancer Therapy Trial by Year-End Oncolytics Biotech® Inc. is engaging with the FDA to potentially launch a pivotal study for pancreatic cancer treatment. The goal is to start trial activities by the year's end.

Oncolytics Biotech® Pursues FDA Study Approval for Pancreatic Cancer Therapy Trial by Year-End #USA #San_Diego #pancreatic_cancer #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

8 months ago

Oncolytics Biotech Successfully Reaffirms Compliance with Nasdaq Listing Standards Oncolytics Biotech has regained compliance with Nasdaq's minimum bid price requirement, ensuring its shares continue trading on the exchange.

Oncolytics Biotech Successfully Reaffirms Compliance with Nasdaq Listing Standards #NASDAQ #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

8 months ago

Oncolytics Biotech Presents New Data on Pelareorep's Effectiveness Across Tumor Types Oncolytics Biotech unveils promising data on Pelareorep, showcasing its potential to treat various tumor types and enhance immune response in cancer therapy.

Oncolytics Biotech Presents New Data on Pelareorep's Effectiveness Across Tumor Types #USA #San_Diego #Immunotherapy #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

8 months ago

Oncolytics Biotech's Webinar to Focus on Immunotherapy Advances for Gastrointestinal Cancers Oncolytics Biotech will host a KOL webinar discussing pelareorep's role in treating pancreatic and gastrointestinal cancers, featuring leading oncology experts.

Oncolytics Biotech's Webinar to Focus on Immunotherapy Advances for Gastrointestinal Cancers #None #San_Diego #Oncolytics_Biotech #pelareorep #Gastrointestinal_Cancer

Thiard News@F4F

@newsen.bsky.social

8 months ago

Oncolytics Biotech® Advances Pelareorep to Transform Cancer Treatments with Promising Survival Data Oncolytics Biotech® shares groundbreaking clinical trial results for Pelareorep, revealing significant survival benefits across multiple cancers and commitment to new studies.

Oncolytics Biotech® Advances Pelareorep to Transform Cancer Treatments with Promising Survival Data #USA #San_Diego #Immunotherapy #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

9 months ago

Oncolytics Biotech Appoints Andrew Aromando as Chief Business Officer to Enhance Business Growth Oncolytics Biotech has appointed Andrew Aromando as Chief Business Officer. With over 30 years in the industry, he will lead global development initiatives.

Oncolytics Biotech Appoints Andrew Aromando as Chief Business Officer to Enhance Business Growth #Canada #Calgary #Oncolytics_Biotech #pelareorep #Andrew_Aromando

Thiard News@F4F

@newsen.bsky.social

9 months ago

Oncolytics Biotech Appoints New CEO to Propel Immunotherapy Advancements Oncolytics Biotech Inc. has appointed Jared Kelly as the new CEO to elevate the company's innovative immunotherapy programs and drive clinical advancements.

Oncolytics Biotech Appoints New CEO to Propel Immunotherapy Advancements #USA #San_Diego #Oncolytics_Biotech #pelareorep #Jared_Kelly

Thiard News@F4F

@newsen.bsky.social

10 months ago

Oncolytics Biotech Unveils Breakthrough Clinical Data on Pelareorep at ASCO 2025 At the ASCO 2025 conference, Oncolytics Biotech Inc. presented significant findings on pelareorep's immune activation capabilities in treating pancreatic cancer.

Oncolytics Biotech Unveils Breakthrough Clinical Data on Pelareorep at ASCO 2025 #USA #San_Diego #Oncolytics_Biotech #pelareorep #ASCO_2025

Thiard News@F4F

@newsen.bsky.social

10 months ago

Oncolytics Biotech Reports Positive Financial Outcomes and Clinical Advances in Immunotherapy Oncolytics Biotech announces its first quarter results and emphasizes the clinical success of pelareorep in treating various cancers, highlighting ongoing trials.

Oncolytics Biotech Reports Positive Financial Outcomes and Clinical Advances in Immunotherapy #Canada #Calgary #Cancer_Immunotherapy #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

11 months ago

Oncolytics Biotech® to Present Promising Findings on Pelareorep for Pancreatic Cancer at ASCO 2025 At the upcoming ASCO meeting, Oncolytics Biotech® will unveil data on Pelareorep's efficacy against pancreatic cancer, showcasing its innovative immune-activating mechanisms.

Oncolytics Biotech® to Present Promising Findings on Pelareorep for Pancreatic Cancer at ASCO 2025 #United_States #Chicago #Oncolytics_Biotech #pelareorep #ASCO

Thiard News@F4F

@newsen.bsky.social

11 months ago

Oncolytics Biotech® and Alumni Capital Enter into Major Financing Agreement for Pelareorep Development Oncolytics Biotech® partners with Alumni Capital in a pivotal financing move, boosting pelareorep's development with a share purchase agreement.

Oncolytics Biotech® and Alumni Capital Enter into Major Financing Agreement for Pelareorep Development #USA #San_Diego #Oncolytics_Biotech #pelareorep #Alumni_Capital

Thiard News@F4F

@newsen.bsky.social

11 months ago

Exploring Cutting-Edge Immunotherapy Developments for Breast and Pancreatic Cancers Oncolytics Biotech® highlights innovative immunotherapy treatments for breast and pancreatic cancers during a recent key opinion leader event.

Exploring Cutting-Edge Immunotherapy Developments for Breast and Pancreatic Cancers #USA #San_Diego #Immunotherapy #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech Highlights 2024 Financial Results and Promising Trial Outcomes Oncolytics Biotech's recent report reveals impressive trial outcomes and financial results for 2024, focusing on innovative cancer therapies and key developments.

Oncolytics Biotech Highlights 2024 Financial Results and Promising Trial Outcomes #Canada #cancer_therapy #Calgary #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

1 year ago

Advancements in Oncology Research: Hopeful Horizons for Cancer Treatments Through 2025 The landscape of cancer research is evolving, marked by significant breakthroughs and insights from prominent institutions and companies, paving the way for innovative therapies.

Advancements in Oncology Research: Hopeful Horizons for Cancer Treatments Through 2025 #USA #Vancouver #Cancer_Research #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech's Strong Regulatory Progress in Oncology Trials for 2025 Oncolytics Biotech®, advancing clinical trials for pancreatic and anal cancer treatments, shows promising regulatory milestones and efficacy signals.

Oncolytics Biotech's Strong Regulatory Progress in Oncology Trials for 2025 #USA #San_Diego #pancreatic_cancer #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech® Makes Major Progress in 2025 Cancer Treatments Oncolytics Biotech® Inc. is advancing its immunotherapy pipeline in 2025, focusing on pancreatic, anal, and metastatic breast cancers with promising results.

Oncolytics Biotech® Makes Major Progress in 2025 Cancer Treatments #USA #San_Diego #Cancer_Treatment #Oncolytics_Biotech #pelareorep

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech® Announces Leadership Change Following CEO's Medical Leave Oncolytics Biotech® has announced that Dr. Matt Coffey will not return as CEO after his medical leave. The search for a new chief executive begins promptly.

Oncolytics Biotech® Announces Leadership Change Following CEO's Medical Leave #USA #San_Diego #Oncolytics_Biotech #pelareorep #Matt_Coffey

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech to Unveil Promising New Data on Anal and Pancreatic Cancer Treatments at 2025 ASCO GI Symposium Oncolytics Biotech will present groundbreaking efficacy and safety data for pelareorep therapy targeting anal and pancreatic cancers at the 2025 ASCO GI Symposium.

Oncolytics Biotech to Unveil Promising New Data on Anal and Pancreatic Cancer Treatments at 2025 ASCO GI Symposium #None #San_Francisco #Oncolytics_Biotech #pelareorep #ASCO_GI

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech's Regulatory Approval Fuels New Hope for Pancreatic Cancer Treatment Advancement Oncolytics Biotech has received essential regulatory approval to continue its trial for a pancreatic cancer treatment. This milestone may lead to improved patient outcomes.

Oncolytics Biotech's Regulatory Approval Fuels New Hope for Pancreatic Cancer Treatment Advancement #United_States #San_Diego #Oncolytics_Biotech #pelareorep #GOBLET_Study

Thiard News@F4F

@newsen.bsky.social

1 year ago

Oncolytics Biotech® Prepares for an Influential 2025 with New Cancer Treatment Data Oncolytics Biotech® reflects on remarkable 2024 achievements while gearing up for significant developments in 2025, focusing on cancer treatments.

Oncolytics Biotech® Prepares for an Influential 2025 with New Cancer Treatment Data #USA #Cancer_Treatment #Oncolytics_Biotech #pelareorep #San_Diego,_CA